Mustang Bio (NASDAQ:MBIO) is a biopharmaceutical company focused on the development of innovative gene and cell therapies. This includes a wide range of treatments for hematologic cancers, solid tumors, and rare genetic diseases. The company's projects harness cutting-edge technology and groundbreaking research in CAR T therapies and gene therapies to address unmet medical needs. Mustang Bio aims to transform patient lives through scientific excellence and dynamic partnerships with leading academic institutions. Their objective is to advance these therapies from the laboratory to clinical trials and ultimately, to patients who need them the most, with a commitment to safety, efficacy, and accessibility.